Prediction of DNA Repair Inhibitor Response in Short-Term Patient-Derived Ovarian Cancer Organoids
Open accessPublished version of a preprint
The DOI matches its Crossref record; 50 of the 50 references it cites were found in a registry or an index.
Abstract
Based on genomic analysis, 50% of high-grade serous ovarian cancers (HGSC) are predicted to have DNA repair defects. Whether this substantial subset of HGSCs actually have functional repair defects remains unknown. Here, we devise a platform for functional profiling of DNA repair in short-term patient-derived HGSC organoids. We tested 33 organoid cultures derived from 22 patients with HGSC for defects in homologous recombination (HR) and replication fork protection. Regardless of DNA repair gene mutational status, a functional defect in HR in the organoids correlated with PARP inhibitor sensitivity. A functional defect in replication fork protection correlated with carboplatin and CHK1 and ATR inhibitor sensitivity. Our results indicate that a combination of genomic analysis and functional testing of organoids allows for the identification of targetable DNA damage repair defects. Larger numbers of patient-derived organoids must be analyzed to determine whether these assays can reproducibly predict patient response in the clinic. Significance: Patient-derived ovarian tumor organoids grow rapidly and match the tumors from which they are derived, both genetically and functionally. These organoids can be used for DNA repair profiling and therapeutic sensitivity testing and provide a rapid means of assessing targetable defects in the parent tumor, offering more suitable treatment options. Cancer Discov; 8(11); 1404–21. ©2018 AACR. This article is highlighted in the In This Issue feature, p. 1333
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“revealing strong correlations between in vitro and in vivo drug responses against cancer in the gastrointestinal tract123, bladder124, ovary125, rectum126 and pancreas127,128.”
From Human disease models in drug development (2023) · cites this paper as [125]
In the citing paper
“PDOs are a validated preclinical model to evaluate anti-cancer drug efficacy [24,25].”
From Combining Mitomycin C with inhibition of BAD phosphorylation enhances apoptotic cell death in advanced cervical cancer (2024) · cites this paper as [24]
In the citing paper
“Patient-derived organoids or tumoroids retain cellular heterogeneity and immune cells, thus are able to more strongly recapitulate a three-dimensional (3D) tumor microenvironment ex vivo compared to homogeneous cell lines (Hill et al., 2018; Kopper et al., 2019).”
From Three-dimensional modelling of ovarian cancer: from cell lines to organoids for discovery and personalized medicine (2022) · cites this paper as Hill et al., 2018
In the citing paper
“Ovarian tumoroid cultures have been established from both ascitic fluid and primary tumors, to date primarily from the more common HGSOC but also from LGSOC, MOC, OCCC, and EnOC (Hill et al., 2018; De Witte et al., 2020; Nanki et al., 2020).”
From Three-dimensional modelling of ovarian cancer: from cell lines to organoids for discovery and personalized medicine (2022) · cites this paper as Hill et al., 2018
In the citing paper
“In contrast, it has been noted that organoid propagation methods tend to be selective and result in a cell population that may not be representative of the original tumor heterogeneity and in turn, treatment response, particularly in patients who have undergone previous neoadjuvant therapy (Hill et al., 2018).”
From Three-dimensional modelling of ovarian cancer: from cell lines to organoids for discovery and personalized medicine (2022) · cites this paper as Hill et al., 2018
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Cerami, E., Gao, J., Dogrusoz, U., Gross, B. E., Sumer, S. O., Aksoy, B. A., Jacobsen, A., Byrne, C. J., Heuer, M. L., Larsson, E., et al. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0095 · Cited by 17,455 · cited 1×
“Mutations were visualized with the cBioPortal OncoPrinter script (47, 48).”
MethodIntegrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal
Gao, J., Aksoy, B. A., Dogrusoz, U., Dresdner, G., Gross, B., Sumer, S. O., Sun, Y., Jacobsen, A., Sinha, R., Larsson, E., et al. (2013) · Science Signaling · doi:10.1126/scisignal.2004088 · Cited by 15,160 · cited 1×
“Mutations were visualized with the cBioPortal OncoPrinter script (47, 48).”
MethodIntegrated genomic analyses of ovarian carcinoma
Perou, C. M. (2019) · Carolina Digital Repository (University of North Carolina at Chapel Hill) · doi:10.17615/hvp3-wg08 · Cited by 7,925
Mermel, C. H., Schumacher, S. E., Hill, B., Meyerson, M. L., Beroukhim, R., & Getz, G. (2011) · Genome Biology · doi:10.1186/gb-2011-12-4-r41 · Cited by 3,550
PARP inhibitors: Synthetic lethality in the clinic
Lord, C. J., & Ashworth, A. (2017) · Science · doi:10.1126/science.aam7344 · Cited by 2,880 · cited 2×
“2 and Table 1), because olaparib sensitivity is a useful surrogate marker for an HR defect (7).”
BackgroundAudeh, M. W., Carmichael, J., Penson, R. T., Friedlander, M., Powell, B., Bell-McGuinn, K. M., Scott, C., Weitzel, J. N., Oaknin, A., Loman, N., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60893-8 · Cited by 2,279
Self-citationOrganoid models of human and mouse ductal pancreatic cancer
Boj, S. F., Hwang, C.-I., Baker, L. A., Chio, I. I. C., Engle, D. D., Corbo, V., Jager, M., Ponz-Sarvise, M., Tiriac, H., Spector, M. S., et al. (2015) · Cell · doi:10.1016/j.cell.2014.12.021 · Cited by 2,150
Drost, J., & Clevers, H. (2018) · Nature Reviews Cancer · doi:10.1038/s41568-018-0007-6 · Cited by 1,790 · cited 1×
“Large-scale studies of organoids, with comparison with patient outcomes, will be required to prove the utility of this model system in the clinic (18, 19, 21).”
ResultWhole–genome characterization of chemoresistant ovarian cancer
Patch, A.-M., Christie, E. L., Etemadmoghadam, D., Garsed, D. W., George, J., Fereday, S., Nones, K., Cowin, P., Alsop, K., Bailey, P. J., et al. (2015) · Nature · doi:10.1038/nature14410 · Cited by 1,569 · cited 2×
“NOVEMBER 2018 CANCER DISCOVERY | 1419 Human tumors derived from several tissue types exhibit clonal heterogeneity (22, 46), and functional assays in organoids can be used to address the effects of genomic tumor heterogeneity on therapeutic response.”
BackgroundOrganoid Cultures Derived from Patients with Advanced Prostate Cancer
Gao, D., Vela, I., Sboner, A., Iaquinta, P. J., Karthaus, W. R., Gopalan, A., Dowling, C., Wanjala, J. N., Undvall, E. A., Arora, V. K., et al. (2014) · Cell · doi:10.1016/j.cell.2014.08.016 · Cited by 1,559
Cited by
Items 401–457 of 457
Data from RAD51 Foci as a Biomarker Predictive of Platinum Chemotherapy Response in Ovarian Cancer
Compadre, A. J., van Biljon, L. N., Valentine, M. C., Llop‐Guevara, A., Graham, E., Fashemi, B., Herencia-Ropero, A., Kotnik, E. N., Cooper, I., Harrington, S. P., et al. (2023) · doi:10.1158/1078-0432.c.6649139
Stossel, C., Raitses‐Gurevich, M., Atias, D., Beller, T., Gorman, Y. G., Halperin, S., Peer, E., Denroche, R. E., Zhang, A. X. W., Notta, F., et al. (2023) · doi:10.1158/2159-8290.c.6742664
Use of Organoids in Cancer: A New Therapeutic and Research Approach
Tonon, S., Martinis, E., Secco, C. D., Tosoni, L., Tomadini, G., Vitale, G., Pucillo, C. E. M., & Frossi, B. (2022) · Springer eBooks · doi:10.1007/978-3-030-80962-1_285-1
A Novel ex-vivo platform for personalized treatment in metastatic ovarian cancerPreprint
Valdivia, A., Adefolaju, A., Thang, M., Cuaboy, L. A., John, C. S., Mann, B., Satterlee, A., Bae-Jump, V. L., & Hingtgen, S. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.03.14.585117
The Role of RAD51C in the Development of Ovarian Cancer: An In Vitro Animal Experiment StudyPreprint
Lü, X., Li, X., Jiang, J., Deng, H., & Lu, C. (2024) · Research Square · doi:10.21203/rs.3.rs-4327289/v1
Patientenabgeleitete 3-D-Tumormodelle: Avatare in der Onkologie
Mateska, I., Stange, D. E., & Ball, C. R. (2024) · Die Onkologie · doi:10.1007/s00761-024-01542-x
Current and future perspectives of xenograft models of human ovarian cancer
Inoue, J., Chiyoda, T., Muramatsu, T., Hirasawa, A., Aoki, D., & Inazawa, J. (2024) · Elsevier eBooks · doi:10.1016/b978-0-12-824040-3.00014-5
Organoids research progress in gynecological cancers: a bibliometric analysis
He, B., Ma, H., Yu, H., Li, D., Zhang, L., & Wang, J. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1484074 · Cited by 1
Serafini, C. E., Davarzani, A., Cappabianca, D., Collazos, D. B., Li, Z., Mamaghani, D., Tommasi, A. M., Sarko, L. E., Denne, N. L. V., Mao, L., et al. (2025) · Quantitative Phase Imaging · doi:10.1117/12.3039313 · Cited by 1
“19 Spheroids accurately replicate the tumor’s microenvironment, cellular heterogeneity, and complex architecture, thereby offering a physiologically relevant alternative to traditional cell cultures and animal models.”
InfluentialOssikbayeva, S., Orazgaliyeva, M., Aidarov, A., Dubchev, D., & Абдрахманов, Р. (2025) · Oncologia i radiologia Kazakhstana · doi:10.52532/2521-6414-2025-2-76-472
Organoids: New Research Tool in Cancer Diagnostics and Therapeutics
Potdar, P. D. (2025) · BENTHAM SCIENCE PUBLISHERS eBooks · doi:10.2174/9789815238693125010009
Use of Organoids in Cancer: A New Therapeutic and Research Approach
Tonon, S., Martinis, E., Secco, C. D., Tosoni, L., Tomadini, G., Vitale, G., Pucillo, C. E. M., & Frossi, B. (2025) · Springer eBooks · doi:10.1007/978-3-032-00771-1_285
Additional file 1 of Sialyl-Tn serves as a potential therapeutic target for ovarian cancer
Al-Alem, L., Prendergast, J. M., Clark, J., Zarrella, B., Zarrella, D. T., Hill, S. J., Growdon, W. B., Pooladanda, V., Spriggs, D. R., Cramer, D. W., et al. (2024) · Figshare · doi:10.6084/m9.figshare.25530160
Self-citationAdditional file 7 of Sialyl-Tn serves as a potential therapeutic target for ovarian cancer
Al-Alem, L., Prendergast, J. M., Clark, J., Zarrella, B., Zarrella, D. T., Hill, S. J., Growdon, W. B., Pooladanda, V., Spriggs, D. R., Cramer, D. W., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26700793
Self-citationCesari, E., Ciucci, A., Pieraccioli, M., Caggiano, C., Nero, C., Bonvissuto, D., Sillano, F., Buttarelli, M., Piermattei, A., Loverro, M., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26590215
Heinze, K., Rengsberger, M., Gajda, M. R., Jansen, L., Osmers, L., Oliveira-Ferrer, L., Schmalfeldt, B., Dürst, M., Häfner, N., & Runnebaum, I. B. (2021) · Figshare · doi:10.6084/m9.figshare.13633212
Additional file 6 of Sialyl-Tn serves as a potential therapeutic target for ovarian cancer
Al-Alem, L., Prendergast, J. M., Clark, J., Zarrella, B., Zarrella, D. T., Hill, S. J., Growdon, W. B., Pooladanda, V., Spriggs, D. R., Cramer, D. W., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26700790
Self-citationCesari, E., Ciucci, A., Pieraccioli, M., Caggiano, C., Nero, C., Bonvissuto, D., Sillano, F., Buttarelli, M., Piermattei, A., Loverro, M., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26590212
Cesari, E., Ciucci, A., Pieraccioli, M., Caggiano, C., Nero, C., Bonvissuto, D., Sillano, F., Buttarelli, M., Piermattei, A., Loverro, M., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26590209
Additional file 3 of Sialyl-Tn serves as a potential therapeutic target for ovarian cancer
Al-Alem, L., Prendergast, J. M., Clark, J., Zarrella, B., Zarrella, D. T., Hill, S. J., Growdon, W. B., Pooladanda, V., Spriggs, D. R., Cramer, D. W., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26700781
Self-citationAdditional file 8 of Sialyl-Tn serves as a potential therapeutic target for ovarian cancer
Al-Alem, L., Prendergast, J. M., Clark, J., Zarrella, B., Zarrella, D. T., Hill, S. J., Growdon, W. B., Pooladanda, V., Spriggs, D. R., Cramer, D. W., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26700796
Self-citationAdditional file 4 of Sialyl-Tn serves as a potential therapeutic target for ovarian cancer
Al-Alem, L., Prendergast, J. M., Clark, J., Zarrella, B., Zarrella, D. T., Hill, S. J., Growdon, W. B., Pooladanda, V., Spriggs, D. R., Cramer, D. W., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26700784
Self-citationCesari, E., Ciucci, A., Pieraccioli, M., Caggiano, C., Nero, C., Bonvissuto, D., Sillano, F., Buttarelli, M., Piermattei, A., Loverro, M., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26590218
Varinelli, L., Battistessa, D., Guagliò, M., Zanutto, S., Illescas, O., Lorenc, E., Pisati, F., Kusamura, S., Cattaneo, L., Sabella, G., et al. (2024) · Figshare · doi:10.6084/m9.figshare.25744371
Additional file 2 of Sialyl-Tn serves as a potential therapeutic target for ovarian cancer
Al-Alem, L., Prendergast, J. M., Clark, J., Zarrella, B., Zarrella, D. T., Hill, S. J., Growdon, W. B., Pooladanda, V., Spriggs, D. R., Cramer, D. W., et al. (2024) · Figshare · doi:10.6084/m9.figshare.25530397
Self-citationAdditional file 5 of Sialyl-Tn serves as a potential therapeutic target for ovarian cancer
Al-Alem, L., Prendergast, J. M., Clark, J., Zarrella, B., Zarrella, D. T., Hill, S. J., Growdon, W. B., Pooladanda, V., Spriggs, D. R., Cramer, D. W., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26700787
Self-citationConstructing an ultrasound-assisted organoid model for tumor management
Li, T., Wang, X., Zhu, M., Han, S., Zhao, D., Wong, V. H. H., Huang, W., Li, Z., Zhao, H., & Qian, X. (2025) · Discover Oncology · doi:10.1007/s12672-025-03963-5
“This accelerates the assessment of drug efficacy and safety, providing valuable insights for clinical decision-making—particularly in cases where tumor progression is exacerbated by treatment delays [8, 9].”
Development and Application of Tumor Organoids: An Emerging Platform for Gynecological Cancers
Hu, Y., Chen, W., Zhang, X., Wu, Y., Du, F., Wang, J., He, M., & Sun, W. T. (2025) · International Journal of Women s Health · doi:10.2147/ijwh.s567162
Preclinical Patient-Derived Tumor Organoids for Modeling Cancer
Somuncu, O. (2026) · Stem cell biology and regenerative medicine · doi:10.1007/978-3-032-10024-5_1
Bladder Organoids for Healthy and Diseased Tissue Modeling
Sevim, S., & Akbulut, D. (2026) · Stem cell biology and regenerative medicine · doi:10.1007/978-3-032-10024-5_2
CELLULAR BIOTECHNOLOGIES IN THE MODELING OF CARCINOGENESIS AND THEIR POTENTIAL IN PRECISION MEDICINE
Куралбаевич, Н. А., Kokanov, S. K., Terebay, A. A., & Marakhovskaya, L. G. (2026) · Biosafety and Biotechnology · doi:10.58318/2957-5702-2025-23-50-84
Patient-Derived Lung Cancer Organoids for Precision Oncology: A Comprehensive Analysis
Chen, D., Sun, Z., Li, J., Wang, X., Li, Y., Mao, Y., & Chen, Y. (2026) · JTO Clinical and Research Reports · doi:10.1016/j.jtocrr.2026.100990 · Cited by 1
“10 More importantly, PDOs enable ex vivo evaluation of the efficacy and resistance to multiple drugs within a short time window, 11,12 bridging the gap between laboratory tests and clinical decision-making.”
Grogan, E., Ozua, O. E., Kavlashvili, T., Conwell, S. C., & Dewar, J. M. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.03.22.666038
Sun, S., Huang, L., Ma, Y., Wei, Z., Zhu, M., Chen, M., Ying, F., Zhou, X., Yang, P., Wen, Y., et al. (2026) · Cell Death and Disease · doi:10.1038/s41419-026-08605-4
“The experimental protocols were ethically sanctioned by the Research Ethics Committee of Union Hospital, af fi liated with Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.”
InfluentialUnmasking prostate cancer risk factors leveraging organoid technology
Cantarelli, M., Marmocchi, E., Lunardi, A., & Begaj, R. (2026) · Gene · doi:10.1016/j.gene.2026.150142
Kim, J. Y., Lee, Y.-K., Shin, H.-Y., Kim, Y. J., Jeon, M. A., Yang, W., Jun, A., Kim, K., Cho, H., Kim, M.-A., et al. (2026) · PLoS ONE · doi:10.1371/journal.pone.0345861
Tatin, X. (2021) · theses.fr (ABES) · doi:10.70675/2e1efdc7ze73bz4150za65dzec3d74346874 · Cited by 1
Boidin, L. (2024) · theses.fr (ABES) · doi:10.70675/085bc588zd389z4852z8217z35c4df4037a2
Trioën, C. (2024) · theses.fr (ABES) · doi:10.70675/7c132518z8997z4d01z8084z87c06a661e5a
Sugawara, M., Nishio, H., Iwata, T., Katoh, Y., Sato, T., & Yamagami, W. (2026) · Journal of Gynecologic Oncology · doi:10.3802/jgo.2026.37.e101
“Among gynecologic cancers, tumor organoids derived from the ovary [25,26], endometrium [27], and cervix [28] have also been reported.”
Fashemi, B., Ota, Y., Gupta, V. G., Elizagaray, M. L., Piqué-Regi, R., Gomez‐Lopez, N., Mullen, M., & Khabele, D. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.06.05.730209
Mes/Stem-A ovarian cancer subtypes predict sensitivity to ATR inhibition
Sundararajan, V., Ziyu, F., Elfar, G. A., Tan, T. Z., Kuay, K. T., Tan, A., Lai, C., Wengner, A. M., Hung, H. T., Qi, M., et al. (2026) · Oncogene · doi:10.1038/s41388-026-03830-9
“Furthermore, testing of VE-822 (ATR inhibitor) and prexasertib (CHK1 inhibitor) on ovarian tumor-derived organoids revealed a direct association between replication fork instability and sensitivity to both aforementioned drugs [59].”
Ragothaman, S., Reddy, R., Sajan, S. C., John, L. A., Biju, V., Vipulachandra, Y., Sankaran, S., Ranade, R. R., & Smitha, P. K. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.06.10.731260
“Cytotoxicity profiles were qualitatively validated in parallel using calcein-AM and ethidium homodimer-1 fluorescence live/dead staining [21,23,24].”
Vigneshwaran, N., Thangam, T., Parthasarathy, K., & Haribalaji, V. (2026) · Clinical & Translational Oncology · doi:10.1007/s12094-026-04458-7
Miedziarek, C., Caputa, P., Bochyński, H., Zaborowski, M. P., & Nowak‐Markwitz, E. (2026) · Cancers · doi:10.3390/cancers18132157
Gall-Mas, L., Moyano‐Galceran, L., Valkonen, E., Hynninen, J., Wennerberg, K., & Senkowski, W. (2026) · STAR Protocols · doi:10.1016/j.xpro.2026.104690
Wendt, J. R., Adams, K. M., Moreno, R., Hossan, M. S., Stram, A., Lin, E. S., Kersten, L., Kratz, J. D., Roy, M., McGregor, S. M., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.07.06.736185
Models of high-grade serous carcinoma of tubo-ovarian origin
Padmanabhan, A., Dwivedi, S. K. D., Merritt, M. A., Verma, P., Buckanovich, R. J., Lang, J. D., Dimmick, H. L., Nephew, K. P., Drapkin, R., Brubaker, L. W., et al. (2026) · Oncology Reviews · doi:10.3389/or.2026.1849834 · Cited by 1
“However, a breakthrough came with the successful establishment of short-term organoid cultures from tumor biopsies of 22 HGSC patients and one low-grade serous carcinoma patient (87).”
Wang, G., Tan, Z., Jia, W., Liu, Y., Wang, H., Sun, W., Sun, W. Z., Meng, L., Zhang, Y., Liu, N., et al. (2026) · Frontiers in Oncology · doi:10.3389/fonc.2026.1880986
“Accordingly, patients harboring targetable mutations often show poor responses to matched targeted therapies (10), which undermines the accuracy of drug response prediction and reduces the precision of personalized treatment.”
RAD54L coordinates the nucleolar DNA damage response to maintain rDNA stability
Liu, R., Xuan, J., Cerra, C., Stojnic, N., Pan, J., Chelliah, S. S., Mendez, S., Dmello, R., Cowley, K. J., Zhang, Y., et al. (2026) · The EMBO Journal · doi:10.1038/s44318-026-00864-3
“Notably, RAD51C loss similarly resulted in increased fork speed; however, fork progression continuity was largely maintained under basal conditions and was reduced following hydroxyurea (HU) treatment, indicating impaired fork protection under replication stress (Hill et al, 2018) (Fig.”
Baratti, D., Varinelli, L., Guagliò, M., Kusamura, S., Cavalleri, T., Battistessa, D., Sabella, G., Colletti, G., Gariboldi, M., & D, M. D. M. (2026) · Cancers · doi:10.3390/cancers18162722 · Cited by 1
Gordiichuk, P., Doronina, M., Ponomarova, O. V., Gordiichuk, M., Shapochka, D., Melnyk, D., & Tereshchenko, A. (2026) · Experimental Oncology · doi:10.15407/exp-oncology.2026.02.133
Tanna, H., & Shah, S. (2026) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2026.2726313
“These cultures are established directly from patient tumor tissue but are maintained in media that omit or substantially reduce ROCK/Rho and TGF-β pathway inhibitors, so that cells are not driven through the full de-differentiation program used to support indefinite long-term expansion [50,56].”
Organoids and AI-integrated models in ovarian cancer research: the future of personalized therapy
Nikam, A., Bhutia, G. T., & Sarkar, S. (2026) · Frontiers in Oncology · doi:10.3389/fonc.2026.1903061
Yoo, J., Kim, Y., Jung, Y., Cho, E., Choi, J. K., Kang, H. G., & Lee, J. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.09.22.753421
“Consequently, various genomic profiling methods–such as quantifying structural variations (SVs), single-nucleotide variants (SNVs), and mutational signatures 5-9 –have been implemented to evaluate baseline HRD status and predict clinical responses to PARPi.”
LiFT: Live foci tracking for quantitative analysis of DNA damage dynamics
de Wolf, T. H., Engbers, P. A. M., Perrin, J., van der Steen, K. H., van Beuningen, S. F. B., Smal, I., & Nonnekens, J. (2026) · Scientific Reports · doi:10.1038/s41598-026-71338-z
Translational applications and clinical utility of organoids in ovarian cancer: a systematic review
Alzahrani, R., & Alghadmi, M. A. (2026) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-026-04973-y
“A total of 13 studies [11, 13, 22, 24, 32–40 ] were identified for inclusion in this systematic review, spanning from 2018 to 2026, after deduplication and excluding studies based on the eligibility criteria.”
Influential
Metadata
- Authors
- Hill, S. J., Decker, B., Roberts, E. A., Horowitz, N. S., Muto, M. G., Worley, M. J., Feltmate, C. M., Nucci, M. R., Swisher, E. M., Nguyen, H., Yang, C., Morizane, R., Kochupurakkal, B. S., Do, K. T., Konstantinopoulos, P. A., Liu, J. F., Bonventre, J. V., Matulonis, U. A., Shapiro, G. I., Berkowitz, R. S., Crum, C. P., & D'Andrea, A. D.
- Affiliations
- Brigham and Women's Hospital (US)
- Harvard University (US)
- University of Washington (US)
- Dana-Farber Cancer Institute (US)
- 1Department of Radiation Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.
- ORCID
- Hill, Sarah J.
- Decker, Brennan
- Roberts, Emma A.
- Horowitz, Neil S.
- Worley, Michael J.
- Feltmate, Colleen M.
- Nucci, Marisa R.
- Swisher, Elizabeth M.
- Nguyen, Huy
- Yang, Chunyu
- Morizane, Ryuji
- Kochupurakkal, Bose S.
- Do, Khanh T.
- Konstantinopoulos, Panagiotis A.
- Liu, Joyce F.
- Bonventre, Joseph V.
- Matulonis, Ursula A.
- Shapiro, Geoffrey I.
- Berkowitz, Ross S.
- Crum, Christopher P.
- Venue
- Cancer Discovery
- Published
- 2018-11-01
- Volume
- 8
- Issue
- 11
- Pages
- 1404-1421
- ISSN
- 2159-8274 (ISSN-L)
- 2159-8290
- PMC
- PMC6365285
- OpenAlex
- W2891058330
- Cited by
- 452
- References
- 49
- Citations by year
- 2026: 37 · 2025: 43 · 2024: 67 · 2023: 78 · 2022: 66 · 2021: 72 · 2020: 63 · 2019: 25 · 2018: 1
- FWCI
- 15.13
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Cancer Discovery (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- Stand Up to Cancer (SU2C) (SU2C-AACR-DT16-15)
- HHS | NIH | National Heart, Lung, and Blood Institute (NHLBI) (R37HL052725, P01HL048546)
- U.S. Department of Defense (DOD) (BC151331P1)
- Leukemia and Lymphoma Society (LLS) (6237-13)
- Breast Cancer Research Foundation (BCRF)
- Richard and Susan Smith Family Foundation
- The Bridge Project
- HHS | NIH | National Cancer Institute (NCI) (UM1 CA186709)
- Topics
- Health Sciences › Medicine › Oncology › PARP inhibition in cancer therapy
- Health Sciences › Medicine › Oncology › Ovarian cancer diagnosis and treatment
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › BRCA gene mutations in cancer
- Keywords
- high-grade serous ovarian cancer, DNA repair deficiency, patient-derived tumor organoids, homologous recombination deficiency, replication fork protection, PARP inhibitor sensitivity, carboplatin sensitivity, CHK1 inhibitor, ATR inhibitors, predictive biomarkers, targeted therapy
- MeSH terms
- Gemcitabine, Antineoplastic Combined Chemotherapy Protocols, Deoxycytidine, DNA Repair, DNA Replication, Female, Follow-Up Studies, Humans, Neoplasm Invasiveness, Neoplasm Recurrence, Local, Organ Culture Techniques, Organoids, Ovarian Neoplasms, Prognosis, Pyrazines, Pyrazoles, Biomarkers, Tumor, Carboplatin, Cystadenocarcinoma, Serous
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.